Intelligent Bio Solutions Launches Interference Study for FDA Clearance of Drug Screening System
Event summary
- Intelligent Bio Solutions has initiated an Interference Study to validate the specificity of its drug screening system in real-world conditions.
- The study, conducted with CenExel Clinical Research, will enroll 75 healthy adult participants and is expected to conclude by mid-July 2026.
- Results will be included in the FDA 510(k) submission package, alongside data from concurrent and prior studies.
- The study aims to demonstrate the system's accuracy in detecting codeine despite potential interfering substances.
The big picture
Intelligent Bio Solutions is advancing its U.S. market entry with a critical clinical study designed to meet FDA requirements for its non-invasive drug screening system. The study's success could validate the company's technology for workplace drug screening, addressing a growing need for reliable, rapid testing solutions in safety-critical industries. The broader implications include potential expansion into other fields beyond drug screening, leveraging fingerprint sweat analysis.
What we're watching
- Regulatory Timeline
- Whether the mid-July 2026 completion date for the Interference Study will allow for a timely FDA 510(k) submission and approval process.
- Market Entry Strategy
- How the company plans to position its drug screening system in the U.S. market, given its existing customer base outside the U.S.
- Technological Validation
- The effectiveness of the system in maintaining accuracy in the presence of potentially interfering substances, which is critical for workplace drug screening.
Related topics